Result for
Topic: Testing and Treatment
November 18, 2020
Remote Household Observation for Non-Influenza Respiratory Viral Illness
Self-collection of swabs was feasible and frequently detected respiratory viruses in a community study, including early detection of circulating SARS-CoV2. Self-collection of nasal swabs (n=678) from households in Seattle (n=303) prior to the COVID-19 pandemic and during the early pandemic period (November 2019 to April 2020) found that 35% of swabs tested positive for one…
November 16, 2020
SARS-CoV-2 Serological Tests Can Generate False Positive Results for Samples from Patients with Chronic Inflammatory Diseases
[Pre-print, not peer-reviewed] Most SARS-CoV-2 serological assays were sensitive to interfering antibodies in samples from patients with chronic inflammatory diseases, which may lead to false positivity. Samples from patients with multiple sclerosis (MS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) were evaluated with 17 commercially-available lateral flow assays. Six of those assays, plus an…
Safety and Efficacy of Inhaled Nebulised Interferon Beta-1a (SNG001) for Treatment of SARS-CoV-2 Infection: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
A phase 2 randomized, double-blind, placebo-controlled trial of inhaled nebulized interferon beta-1a (SNG001) for patients hospitalized with COVID-19 (n=101) found that patients who received the study drug had greater odds of improvement on the WHO ordinal scale for clinical improvement (OSCI) (OR = 2.32) on day 15 or 16 and were more likely to recover…
November 13, 2020
Assessment of SARS-CoV-2 RNA Test Results Among Patients Who Recovered From COVID-19 With Prior Negative Results
A prospective study of 176 Italians who had recovered from COVID-19 and previously tested negative for SARS-CoV-2 RNA via RT-PCR (two negative tests 24 hours apart) found that 32 people (18%) re-tested positive for SARS-CoV-2 (mean of 49 days since initial diagnosis), and one person (3%) was found to have replicative SARS-CoV-2 RNA. It was…
Comparison of SARS-COV-2 Nasal Antigen Test to Nasopharyngeal RT-PCR in Mildly Symptomatic Patients
[Pre-print, not peer-reviewed] A study evaluating the diagnostic performance of a rapid antigen detection test (RADT) indicated that the sensitivity and specificity were 82.1% and 99.1% respectively in patients with mild COVID-19 in a high incidence setting, and the performance was especially high among samples with a high viral load. Nasal samples from male patients…
Validation and Testing of a Method for Detection of SARS-CoV-2 RNA in Healthy Human Stool
[Pre-print, not peer-reviewed] An assay designed to detect SARS-CoV-2 RNA in stool based upon a modified version of the CDC rRT-PCR SARS-CoV-2 test. Using stool samples from health individuals spiked with inactivated SAR-CoV-2 virus, the lower limit of detection (LoD) of the assay was found to be 3,000 viral RNA copies per gram of original…
Performance of Nucleic Acid Amplification Tests for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 in Prospectively Pooled Specimens
A study evaluating the test performance characteristics of 3 nucleic acid amplification tests for SARS-CoV-2 found that the positive percent agreement (PPA) of pooled versus individual testing ranged from 71.7% to 82.6% for pools of 8 and from 82.9% to 100.0% for pools of 4. Pooled samples showed decreased PPA relative to individual samples. False…
Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19
In a double-blind, randomized trial, adult outpatients with mild symptomatic COVID-19 treated with the SSRI antidepressant drug fluvoxamine had a lower likelihood of clinical deterioration over 15 days compared to placebo (8.7% absolute difference). The study included 152 participants and was conducted without patient contact. Clinical deterioration was defined as both (1) having shortness of…
November 9, 2020
Differences of SARS-CoV-2 Serological Test Performance between Hospitalized and Outpatient COVID-19 Cases
A study evaluating two commercially available SARS-CoV-2 serological assays (Virotech, VT-assays and Euroimmun, EI-assays) among using 116 COVID-19 cases (51 inpatients and 65 outpatients) reported the sensitivity of the VT-assay against IgA and IgG was markedly lower among outpatients than inpatients (IgA: 6% vs. 64%; IgG: 86% vs. 96%). The sensitivity of the EI-assay against…
Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19: A Randomized Clinical Trial
A multicenter, blinded, placebo-controlled randomized trial among 479 patients hospitalized with SARS-CoV-2 infection reported that treatment with hydroxychloroquine was not associated with changes in clinical status (on an ordinal scale from 1 as death to 7 as discharged with normal activities) 14 days following randomization (aOR 1.0, 95% CI 0.7-1.4), nor mortality 28 days following…
Previous page Next page